BCM Legacy Fund
Status
ACTIVE
Global HQ
Houston, United States
Countries of investment
- United States
Investment stages
- Pre-Seed
- Seed
Industries
- Biotechnology
- Life Sciences
- Pharma
- Biology
- Science
About
BCM Legacy Fund I, LP is an early-stage biomedical venture fund affiliated with Baylor College of Medicine in Houston, managed by Legacy Fund Management Company, LLC and launched in November 2026. It pools philanthropic capital from private foundations and donor-advised funds, with the Greater Houston Community Foundation as its philanthropic partner, and plans to back about 15 early-stage companies over five years. The fund size was not disclosed. Its first investment is Nemea Therapeutics, a Houston spinout of Baylor and the Lead Discovery Center in Germany developing an oral drug for metastatic triple-negative breast cancer.
BCM Legacy Fund I, LP is an early-stage biomedical venture fund affiliated with Baylor College of Medicine in Houston, managed by Legacy Fund Management Company, LLC and launched in November 2026. It pools philanthropic capital from private foundations and donor-advised funds, with the Greater Houston Community Foundation as its philanthropic partner, and plans to back about 15 early-stage companies over five years. The fund size was not disclosed. Its first investment is Nemea Therapeutics, a Houston spinout of Baylor and the Lead Discovery Center in Germany developing an oral drug for metastatic triple-negative breast cancer.
Investment Thesis
BCM Legacy Fund invests philanthropic capital in biomedical startups built on academic research, especially therapeutics for unmet needs such as rare and pediatric diseases. It backs companies at the earliest and most underfunded stage, sizing each investment to produce a minimum partner-ready dataset so that industry partners, disease foundations or later-stage investors can take over. It differs from conventional venture funds through its philanthropic limited partners, its affiliation with Baylor College of Medicine and its use of innovation maps and AI-assisted diligence to surface overlooked science.
Manager's Experience
Steve Lehmann previously led the University of Chicago's Innovation Fund and built the venture investments practice at Portal Innovations. Burton Hanson is a Houston entrepreneur and investor and a board member of the Fondren Foundation. Board member Debra McCoy is a former BlackRock managing director and Bain and Company partner, and senior strategic advisor Dr. Paul Klotman is the former president and CEO of Baylor College of Medicine.
Team
Burton Hanson - Managing Partner
Steve Lehmann - Managing Partner
Debra McCoy - Board of Managers
Paul Thomas - Board of Managers
Paul Klotman - Senior Strategic Advisor
Portfolio
Nemea Therapeutics